Atorvastatin · Atorvaliq, Lipitor

What is Atorvastatin?

Atorvastatin is an approved small-molecule drug studied in Hypercholesterolemia, Dyslipidemias, Healthy.

At a glance

Also known as

Atorvaliq, Lipitor

Drug type

Small molecule

Targets

HMG-CoA reductase (HMGCR)

Mechanism

Inhibitor of HMG-CoA reductase (HMGCR)

Pathways

cholesterol synthesis, LDL receptor upregulation, LDL uptake and catabolism

Therapy area

Gastroenterology, Metabolic

Developer

Upjohn

In trials of

AKBA, ALGS, ALT, CPIX, EOCN

FDA status

Approved as Atorvaliq, Lipitor (December 17, 1996), NDA020702 · FDA label

✅ FDA-approved uses

• Reduce the risk of myocardial infarction, stroke, revascularization procedures, and angina in adults with multiple risk factors for CHD (Lipitor)
• Reduce the risk of MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD (Lipitor)
• Reduce the risk of non-fatal MI, fatal and non-fatal stroke, revascularization, hospitalization for congestive heart failure, and angina in adults wit (Lipitor)
• Adjunct to diet to reduce LDL-C in primary hyperlipidemia (Lipitor)
• Adjunct to diet to reduce LDL-C in heterozygous familial hypercholesterolemia (adults and pediatric patients aged 10 years and older) (Lipitor)
• Adjunct to other LDL-C-lowering therapies to reduce LDL-C in homozygous familial hypercholesterolemia (Lipitor)
• Adjunct to diet for primary dysbetalipoproteinemia (Lipitor)
• Adjunct to diet for hypertriglyceridemia (Lipitor)

From the indications section of the FDA label (version of Apr 15, 2024). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Drug Interaction PotentiationDyslipidemiasHealthyHealthy VolunteersHypercholesterolemiaNASH - Nonalcoholic Steatohepatitis

Sources

• FDA label (DailyMed)
• FDA label Atorvaliq (2024-04-27), indications
• FDA label Lipitor (2024-04-15), indications
• NCI Thesaurus
• ClinicalTrials.gov NCT03611010

Updated Oct 11, 2026.